Anavex Life Sciences Corp (AVXL)

[boi568]

If blarcamesine is accepted into the pilot program, I think the FDA would not reject it based on the current guidance that require the ADL endpoint. That would be very publicly counterproductive for the agency. They would find a way around it. The trick will be getting into the new program.